Opdualag is “likely to first take metastatic melanoma share from...

Opdualag is “likely to first take metastatic melanoma share from single-agent anti-PD1,” SVB Leerink analyst Daina Graybosch, Ph.D., wrote in a note Wednesday.
Plus, the fixed-dose nature will also prevent physicians from substituting Keytruda for Opdivo in the new combo, she noted. But it will be harder for the new combo to erode share from the Opdivo-Yervoy doublet, she said, given doctor experience with the latter and its seemingly better efficacy.
First-line melanoma is just the first step BMS has planned for Opdualag. The phase 3 RELATIVITY-098 trial is assessing the Opdivo-plus-relatlimab cocktail versus Opdivo alone in postsurgery treatment of stages 3 to 4 melanoma in the adjuvant setting.
The company will soon launch a registrational study for the new combo in second-line colorectal cancer,Hirawat said, and phase 2studies are underway in non-small cell lung cancer and liver cancer.
The Opdualag approval comes on the heels of a high-profile failure for BMS in the melanoma space.

BMS paid $1.85 billion upfront in 2018 to pair with Opdivo, bombed in a phase 3 trial in first-line melanoma.

The drug, used in combination with Opdivo, failed to provide a benefit across tumor shrinkage, disease progression or patient survival, dealing a blow to BMS’ I-O ambition.

So, how much would Eftilagamod Alpha be worth to BMS/ Merck/Roche/Novartis et al....?